Loading stock…

Sartorius Stedim Biotech S.A. (DIM) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Sartorius Stedim Biotech S.A.

DIMMarket cap $24BPrice $243.0

Country🇫🇷France

SectorHealthcare

IndustryLife Sciences

Makes single-use bioreactors, filtration systems, and lab equipment that biotech and pharma companies use to manufacture drugs and vaccines. Nearly every major COVID vaccine producer relied on its disposable bioprocessing technology to scale production fast.

In Bastion Portfolios?

52W Return+3%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-2%2

Revenue Forecast

Rev CAGR (1y)+1%3

Rev CAGR (3y)+9%6

Rev CAGR (5y)+10%7

Earnings Forecast

EPS Growth Y+1+195%10

EPS Growth Y+2+21%8

EPS Growth Y+3+18%8

Quality

Margins

EBIT Margin19%7

Net Income Margin10%5

Free Cash Flow Margin13%7

Debt

Net Debt/EBITDA2.63

Efficiency

ROE7%3

ROA4%5

Earnings Stability55

GEAR+WEAK23

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)392

P/E Ratio (Forward 3y)302

P/BV5.03

EV Multiples

EV/EBITDA Fwd232

EV/EBIT Fwd372

Yield

Free Cash Flow Yield1.9%4

Dividend Yield0.3%1

Momentum

Short term

1 month return+15%10

3 month return+19%9

YTD return+2%5

Mid term

Price vs 52wHigh96%10

1 year return+9%6

Long term

3 year return-6%2

5 year return-51%1

Risk Shield

Price Risk

Beta1.32

Volatility40%4

Free Cash Flow

Free Cash Flow Margin13%7

Free Cash Flow Yield1.9%4

Quality

ROCE8%5

Earnings Stability55

Net Debt/EBITDA2.63

02Growth

Is it actually growing, and how fast?

DIMSartorius Stedim Biotech S.A.

Revenue FY25$2.9B

GROWTH RATING↗

AVERAGE54 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-2%2

Revenue, next 1Y+1%3

Revenue, next 3Y, CAGR+9%6

Revenue, next 5Y, CAGR+10%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+195%10

EPS growth, FY27E+21%8

EPS growth, FY28E+18%8

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to grow 9%/yr from here.

The runway holds up: revenue is set to grow 10%/yr over five years.7/10

Earnings are set to grow faster than sales (EPS about 21%/yr vs revenue 9%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 54% of companies worldwide.

Revenue is set to grow 9%/yr over the next 3 years, in line with the market.5/10

WEAKNESSES

Revenue fell 2%/yr over the last 3 years, behind 80% of companies worldwide.2/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

DIMSartorius Stedim Biotech S.A.

Total return Current293%

Price return Current279%

MOMENTUM RATING↗

STRONG69 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+15%10

3-month return+19%9

YTD return+2%5

MID & LONG-TERM▾SCORE

% of 52-week high96%10

1-year return+9%6

3-year return-6%2

5-year return-51%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 9% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+15%) and over three months (+19%).

WATCH

Returns sit at the market level so far this year (+2%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-5.5% over three years and -51% over five), behind 80% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Sartorius. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

DIMSartorius Stedim Biotech S.A.

Revenue FY25$2.9B

GROWTH RATING↗

AVERAGE54 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-2%2

Revenue, next 1Y+1%3

Revenue, next 3Y, CAGR+9%6

Revenue, next 5Y, CAGR+10%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+195%10

EPS growth, FY27E+21%8

EPS growth, FY28E+18%8

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to grow 9%/yr from here.

The runway holds up: revenue is set to grow 10%/yr over five years.7/10

Earnings are set to grow faster than sales (EPS about 21%/yr vs revenue 9%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 54% of companies worldwide.

Revenue is set to grow 9%/yr over the next 3 years, in line with the market.5/10

WEAKNESSES

Revenue fell 2%/yr over the last 3 years, behind 80% of companies worldwide.2/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

DIMSartorius Stedim Biotech S.A.

Total return Current293%

Price return Current279%

MOMENTUM RATING↗

STRONG69 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+15%10

3-month return+19%9

YTD return+2%5

MID & LONG-TERM▾SCORE

% of 52-week high96%10

1-year return+9%6

3-year return-6%2

5-year return-51%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 9% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+15%) and over three months (+19%).

WATCH

Returns sit at the market level so far this year (+2%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-5.5% over three years and -51% over five), behind 80% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Sartorius. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community